Jess Rabourn, CFA

Jess Rabourn is the founder and CEO of WideTrial, an early-stage company that serves as a third-party sponsor of multi-site, large-group Expanded Access programs. Since 2010 he has been a nationally recognized speaker on pre-approval access and, through his consulting company and non-profit projects, has provided substantial education and policy support on the topic. He is a member of the American Academy of Neurology and was lead author of the Expanded Access section of the submitted draft for FDA’s Guidance on ALS Drug Development. Prior to this work, Jess spent 15 years in the investment management industry at firms in San Francisco and New York. He earned the Chartered Financial Analyst designation in 2004.